Misplaced Pages

#511488

43-646: Astellas is a member of the Mitsubishi UFJ Financial Group (MUFJ) keiretsu . Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka , and was renamed Fujisawa Pharmaceutical Co. in 1943. Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942. Both companies started their overseas expansion at about

86-586: A "merger of equals," forming Astellas Pharma on 1 April 2005. At least some of its older products continue to be distributed under the original brand, ostensibly due to high brand-name recognition. Astellas had a collaboration agreement with CoMentis from 2008 to 2014 focused on development of beta-secretase inhibitor therapeutics for Alzheimer's disease . In 2009, the company's tacrolimus-containing products Prograf and Advagraf showed they were prone to dosing errors within Europe, leading to serious adverse reactions among

129-538: A Japanese bank holding and financial services company headquartered in Chiyoda, Tokyo , Japan. MUFG was created in 2005 by merger between Mitsubishi Tokyo Financial Group ( 株式会社三菱東京フィナンシャル・グループ , Kabushiki kaisha mitsubishi tōkyō finansharu gurūpu ) and UFJ Holdings (株式会社UFJホールディングス; kabushikigaisha yūefujei hōrudingusu ). These two groups in turn brought together multiple predecessor banks including Mitsubishi Bank (est. 1880), Yokohama Specie Bank (est. 1880 as

172-459: A further $ 176.5 million upon the achievement of predetermined milestones. In May 2023, the business announced it would acquire Iveric Bio for $ 5.9 billion. In November, Astellas announced it would acquire Propella Therapeutics, Inc. and its lead androgen biosynthesis inhibitor abiraterone decanoate (PRL-02) used to treat prostate cancer. The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this

215-694: A large minority shareholder in the Master Trust Bank of Japan , Morgan Stanley in the United States, Security Bank in the Philippines, and Vietinbank in Vietnam. It retains strong links with the Mitsubishi Group and is often described as one of that group’s "Three Great Houses", together with Mitsubishi Corporation and Mitsubishi Heavy Industries . MUFG is Japan's largest financial group and one of

258-479: A monoclonal antibody targeting Claudin 18.2 (CLDN18.2), for the treatment of HER2-negative gastric or gastroesophageal junction adenocarcinoma . Zolbetuximab is the first treatment of its kind in the region, and a decision on its approval is expected by 12 January 2024, based on the Phase III SPOTLIGHT and GLOW clinical trial results. In 2007, the company narrowed UK distribution of Advagraf and Prograf to

301-499: A number of patients, due to deficits in packaging and labeling, deficits corrected after a warning from the UK MHRA . On June 9, 2010, Astellas acquired OSI Pharmaceuticals for $ 4.0 billion. In December 2014, Astellas expanded its 18-month-old collaboration with Cytokinetics, focusing on the R&;D and commercialization of skeletal muscle activators. The companies announced they will advance

344-764: A policy bank, reorganized after World War II as Bank of Tokyo ), Sanwa Bank (est. 1933 by merger of prior institutions), and Tokai Bank (est. 1941 by merger). MUFG holds assets of around US$ 2.7 trillion as of 2024 and is the parent company of fully-owned MUFG Bank (branded Bank of Tokyo Mitsubishi UFJ or BTMU until July 2018 ), Mitsubishi UFJ Trust and Banking Corporation , Mitsubishi UFJ Securities , Mitsubishi UFJ Capital , and MUFG Americas Holdings Corporation ; majority shareholder of Bank Danamon in Indonesia, Bank of Ayudhya in Thailand, and Mitsubishi UFJ NICOS in Japan; and

387-704: A sole distributor, UniChem, in reaction to pharmacist complaints about drug availability from wholesale sources. This narrow distribution was revised to three firms in 2010, covering all of its products in the UK: AAH, Alliance Healthcare , and Phoenix Healthcare Distribution. The company's headquarters are in Tokyo , with research centers in Tsukuba and Osaka . Clinical development is centered in Northbrook, Illinois , La Jolla, California , and Leiden , Netherlands. Combined revenues of

430-628: A total of eight drugs". In December 2018, the Prescription Medicines Code of Practice Authority (PMCPA) published their findings following an allegation that Astellas had "inappropriately awarded research funding" to a senior clinician at a British hospital, directly resulting in the hospital adopting a protocol which was subsequently abandoned less than three years later "because of poor outcomes". This report also reprimanded Astellas for failing to provide sufficient and timely information to investigators. In April 2019, Astellas agreed to pay

473-427: A total €800 million, strengthening its late-stage pipeline with Ogeda's drug candidate, fezolinetant . In November 2017, the company announced that it exercised an option to purchase Cambridge, Massachusetts-based Mitobridge, which is developing treatments for Duchenne muscular dystrophy and age-related diseases . In August 2018, Astellas announced it would acquire Quethera Limited for $ 109 million. In December 2018,

SECTION 10

#1732854799512

516-457: A way that they exaggerate the benefits of treatments". The ABPI responded that medicines were "tested against the most effective comparator where possible unless there is no current standard of care." Regarding "results that companies don't like, [which] they are perfectly entitled to hide [..] from doctors and patients ... academic papers, which everyone thinks of as objective, are often covertly planned and written by people who work directly for

559-1183: Is in London with three regional offices in Cardiff , Belfast and Edinburgh . Membership of the Association of the British Pharmaceutical Industry is not open to individuals, only companies. Members fall into three categories: The ABPI represents the views of the research-based sector of the pharmaceutical industry to government and decision makers in the UK, i.e. is a lobbying organization . The organisation has six departments; Innovation & Research, Patient Access; International Policy & UK Competitiveness; Medical Affairs & Strategic Partnerships; Corporate Affairs & Strategy; Legal and Membership Services. The Medical Affairs & Strategic Partnerships department oversees complimentary resources for schools in UK to promote links between school science subjects and their applications in industrial research. The department also provides information about careers in

602-579: Is not a comprehensive list): In June 2016, the Association of the British Pharmaceutical Industry (ABPI) gave Astellas a year-long suspension, after complaints it had "purposely misled the PMCPA." In particular, Astellas had not fully disclosed the nature of a meeting which had purported to be a "genuine advisory board". In May 2017, the ABPI extended the suspension by a further 12 months, based on findings that Astellas

645-606: Is the British equivalent of America's PhRMA ; however, the member companies research, develop, manufacture and supply medicines prescribed for the National Health Service . The organisation was founded in London in 1891 and originally known as the "Drug Club". It was re-named the Association of the British Pharmaceutical Industry in 1948. A rival institution to represent wholesalers, the "Northern Wholesale Druggists' Association",

688-529: The 2008 ALB Japan Law Awards , Mitsubishi UFJ was crowned: In April 2011, MUFG and Morgan Stanley entered into an agreement to convert MUFG's outstanding convertible preferred stock in Morgan Stanley into Morgan Stanley stock. In June 2011, MUFG took a 9.99 percent stake in Lynas Corp, an Australian rare earths developer. On April 1, 2018, the bank was renamed to MUFG Bank Ltd. This name change aligned

731-499: The Financial Stability Board . MUFG was formed by three successive mergers in a sequence that lasted less than a decade, respectively between Bank of Tokyo and Mitsubishi Bank in 1996, between Sanwa Bank , Tokai Bank and Toyo Trust and Banking in 2000-2002, and between the two resulting entities in 2005. The institutions involved in these mergers combined multiple threads of Japanese financial history, going back to

774-470: The United States Department of Justice $ 100 million to resolve allegations that it had conspired to offer kickbacks via Medicare copay foundations. Astellas' franchise areas are oncology , urology , immunology ( transplantation ), cardiology , and infectious disease . Priority areas for R&D are infectious diseases , diabetes , gastrointestinal diseases , oncology , and diseases of

817-625: The Yokohama Specie Bank in 1880, while Mitsubishi Bank had had a stronger focus on domestic corporate and retail banking. Both banks were relatively healthy in the wake of the Japanese asset price bubble . The merged bank was the fully-owned subsidiary of Mitsubishi Tokyo Financial Group (MTFG), based in Tokyo. Until the Tokyo-Mitsubishi merger in 1996, Sanwa Bank , which was based in Osaka and

860-421: The central nervous system . Recently noted, Astellas Venture Management has funded Oncorus, which recently raised $ 79.5 million in a series B financing round to move two oncolytic viruses through development. Some of the main products produced by Astellas include: The US Food and Drug Administration (FDA) has granted priority review to Astellas Pharma's biologics licence application (BLA) for Zolbetuximab ,

903-632: The yakuza crime syndicates. The takeover of UFJ by the Mitsubishi Tokyo Financial Group was challenged by the Sumitomo Mitsui Financial Group which launched a competing takeover bid. MTFG ultimately prevailed in the fight, which appeared to signal an end to the clubby atmosphere that had prevailed in Japan's postwar banking industry. MUFG and SMFG eventually settled the legal dispute for 2.5 billion yen in late 2006. The merged holding company MUFG, based on Tokyo,

SECTION 20

#1732854799512

946-567: The Competition and Markets Authority (CMA) and the Serious Fraud Office (SFO). It is administered by the Prescription Medicines Code of Practice Authority (PMCPA). Ben Goldacre criticised the pharmaceutical industry in his 2012 book Bad Pharma as testing itself what it manufactures in "poorly designed trials, on hopelessly small numbers of weird, unrepresentative patients, and analysed using techniques that are flawed by design, in such

989-475: The New York Stock Exchange in 1999. In 2008, BTMU purchased all of the outstanding shares of UnionBanCal. BTMU moved its New York-based banking operations to Union Bank and renamed the company MUFG Union Bank in 2014. BTMU was investigated by New York banking regulators over its role in routing payments for Iranian customers through its New York branch in violation of U.S. sanctions. BTMU settled with

1032-434: The UK. It also covers interactions between the industry and health professionals. The ABPI Code sets standards relating to the provision of information about prescription-only medicines to the public and patients, and pharmaceutical companies’ relationships with patient organisations. The ABPI Code does not cover the promotion of over-the-counter medicines to the public. All ABPI member companies are obliged to comply with both

1075-559: The bank name with the holding company name by removing "Tokyo" from the name. On 31 October 2018, MUFG to acquire Australian Asset Manager, Colonial First State Global Asset Management. As of 31 March 2013: Association of the British Pharmaceutical Industry The Association of the British Pharmaceutical Industry ( ABPI ) is the trade association for over 120 companies in the UK producing prescription medicines for humans, founded in 1891. It

1118-823: The company announced it would acquire Potenza Therapeutics, Inc. In December 2019, Astellas Pharma announced it would buy Audentes Therapeutics Inc for approximately $ 3 billion in cash as well as acquiring Xyphos Biosciences, Inc later in the same month. Audentes will operate as a wholly owned subsidiary within Astellas, and will serve as the Center of Excellence for the newly created Genetic Regulation Primary Focus, providing leadership for AAV pipeline advancement through commercialization, manufacturing expansion, and next-generation research initiatives. The acquisition includes Astellas gaining Xyphos’ Advanced Cellular Control through Engineered Ligands (ACCEL) technology platform. On February 5, 2020,

1161-408: The company announced management changes effective from April 1, 2020. Astellas Pharma's Smyraf (ingredient: peficitinib ) obtained regulatory approval for the treatment of rheumatoid arthritis , the third oral Janus kinase (JAK) inhibitor to receive approval. In October 2020, Astellas announced it would acquire iota Biosciences, Inc. for $ 127.5 million, with shareholders eligible to receive up to

1204-464: The development of CK-2127107 (a fast skeletal troponin activator) into Phase II clinical trials for the treatment of spinal muscular atrophy and possibly other neuromuscular conditions. The collaboration was expected to generate more than $ 600 million for Cytokinetics, as well as $ 75 million in milestone payments. In November 2015, the company announced its move to acquire Ocata Therapeutics (formerly Advanced Cell Technology) for $ 379 million. The deal

1247-665: The early Meiji era . MUFG incorporates several of the National Banks in Meiji Japan , which were numbered in accordance with their chronological date of establishment between 1873 and 1880: Mitsubishi Bank and the Bank of Tokyo merged in 1996 to form the Bank of Tokyo-Mitsubishi, which at that point was the world's largest bank in terms of total assets. The Bank of Tokyo had historically focused on foreign exchange business since its foundation as

1290-435: The employees of its predecessor companies. UFJ was one of the largest shareholders of Toyota . The Chairman of Toyota was a director on its board during the financial scandals and indictments of three UFJ executives. In July 2004, UFJ Holdings, by then Japan's fourth-largest financial group, offered to merge with the Mitsubishi Tokyo Financial Group. UFJ had been accused by the government of corruption and making bad loans to

1333-451: The merger and the combined company was to be called United Financial Holdings. The merger was completed in 2002 and the new bank was officially named UFJ Bank Ltd. UFJ Bank was headquartered in Nagoya , the historical headquarters of Tokai Bank, while its parent UFJ Holdings (UFJH) was based in Osaka . During its short life, the group was plagued by bad debt problems and by infighting between

Astellas Pharma - Misplaced Pages Continue

1376-486: The pharmaceutical sector. The association sponsors booklets on a range of conditions, aimed at patients, carers and healthcare professionals. The ABPI Code of Practice covers the promotion of medicines for prescribing to health professionals and administrative staff as well as the provision of information to the public about prescription only medicines in the UK. The Code sets standards for the promotion of medicines to health professionals and other relevant decision makers in

1419-572: The same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards. Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D center in Deerfield, Illinois . Yamanouchi's R&D center in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991. Fujisawa and Yamanouchi combined in

1462-702: The spirit and letter of the Code. The ABPI Code is a self-regulatory code, first established by the ABPI in 1958 and undergoes revisions at least every two years. It is regularly updated and reviewed in consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), the British Medical Association (BMA), the Royal Pharmaceutical Society (RPS), the Royal College of Nursing (RCN),

1505-465: The state for $ 250 million in 2013. A second settlement was reached for $ 315 million in 2014 after it was found that PricewaterhouseCoopers had altered an investigation report on the issue; PwC itself was fined $ 25 million in relation to the matter. In September 2008, MUFG signed a letter of intent with Morgan Stanley to form an alliance and purchase 20% of the American firm. In 2008 at

1548-550: The two banking giants, caused the merger of the banks to be postponed for three months. The trust banking and securities units of MTFG and UFJ were merged according to the original schedule on 1 October 2005. Mitsubishi Bank and the Bank of Tokyo each had significant banking subsidiaries in California ( Bank of California and Union Bank respectively) before their merger. At the time of the merger, these U.S. banks also merged to form UnionBanCal Corporation . BTM listed UnionBanCal on

1591-399: The two pre-merger companies were $ 7.9 billion in 2004. Worldwide the company employs about 17,000 people. The United States subsidiary of Astellas is Astellas US LLC . The company's advertising slogans are: Mitsubishi UFJ Financial Group Mitsubishi UFJ Financial Group, Inc. ( MUFG ; 株式会社三菱UFJフィナンシャル・グループ , Kabushiki gaisha Mitsubishi Yūefujei Finansharu Gurūpu ) is

1634-410: The world's ten largest bank holding companies holding around US$ 1.5 trillion (JP¥227 trillion) in deposits as of April 2024. In Japan, it is the largest of the three so-called megabanks with $ 2.9 trillion in total assets at end-March 2023, ahead of SMBC Group ($ 2.0 trillion) and Mizuho Financial Group ($ 1.9 trillion). It has been consistently listed as a systemically important bank by

1677-546: Was completed in February 2016. Later in November 2015 the company announced it would sell its dermatology business to LEO Pharma for $ 725 million. In October 2016 Astellas announced it would acquire Ganymed Pharmaceuticals for $ 1.4 billion In March 2017, the company sold 16 of its drugs to LTL Pharma for ¥20.1 billion ($ 133 million). In April 2017, the company announced it would acquire Belgium-based drug discovery firm Ogeda for up to

1720-481: Was formed in 1902 and lasted until 1966. A board of management of members oversee the ABPI. The Board is made up of individuals who are elected by members to represent the industry and up to five people who are co-opted by the Board. Elections commence every January for elected seats to ensure that the Board is fully representative and has access to the broadest range of skills and expertise possible. The ABPI's head office

1763-412: Was formed on 1 October 2005 from the merger of MTFG and UFJH. The two banks, Bank of Tokyo-Mitsubishi and UFJ Bank, merged on 1 January 2006 to form MUFG Bank . The latter transaction was originally scheduled to take place on 1 October 2005, the same day that the parent companies were merged. However, pressure from Japan's Financial Services Agency , which wanted to ensure the smooth systems integration of

Astellas Pharma - Misplaced Pages Continue

1806-422: Was not adequately overseeing and training nurses, and that it had failed to provide complete prescribing information for several medicines. In June 2017, Astellas was reprimanded for "producing a large number of promotional materials, which had been used for a number of years, that did not include the required prescribing information related to some serious or common adverse reactions, warnings, and precautions, for

1849-584: Was the anchor of the Sanwa Group keiretsu , had been considered the strongest bank in Japan, and it had aimed to be the world's largest bank during the "bubble era". By 2000, however, Sanwa was the fourth largest bank in Japan. It entered into merger talks with two other large banks, Asahi Bank and Tokai Bank , to create the world's third-largest bank by assets. Asahi pulled out of these talks later that year, and eventually became part of Resona Holdings . By 2001, The Toyo Trust & Banking Co. had been added to

#511488